CN108048402A - A kind of people's Pancytopenia glucocorticoid drug-resistant cell strain and its construction method and application - Google Patents
A kind of people's Pancytopenia glucocorticoid drug-resistant cell strain and its construction method and application Download PDFInfo
- Publication number
- CN108048402A CN108048402A CN201810072930.6A CN201810072930A CN108048402A CN 108048402 A CN108048402 A CN 108048402A CN 201810072930 A CN201810072930 A CN 201810072930A CN 108048402 A CN108048402 A CN 108048402A
- Authority
- CN
- China
- Prior art keywords
- pancytopenia
- cell
- people
- cem
- hdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010033661 Pancytopenia Diseases 0.000 title claims abstract description 51
- 239000003862 glucocorticoid Substances 0.000 title claims abstract description 28
- 238000010276 construction Methods 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 37
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 30
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 30
- 229940079593 drug Drugs 0.000 claims abstract description 30
- 206010059866 Drug resistance Diseases 0.000 claims abstract description 21
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims abstract description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims abstract description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims abstract description 6
- 238000011160 research Methods 0.000 claims abstract description 6
- 230000007246 mechanism Effects 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 174
- 206010021143 Hypoxia Diseases 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 230000007954 hypoxia Effects 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 8
- 238000011081 inoculation Methods 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 6
- 238000004088 simulation Methods 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 210000002751 lymph Anatomy 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 208000018875 hypoxemia Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 238000002386 leaching Methods 0.000 claims 1
- 238000011604 leukemia animal model Methods 0.000 claims 1
- 230000006698 induction Effects 0.000 abstract description 4
- 238000012827 research and development Methods 0.000 abstract description 4
- 230000008506 pathogenesis Effects 0.000 abstract description 3
- 230000004069 differentiation Effects 0.000 abstract 1
- 239000000835 fiber Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 21
- 230000012010 growth Effects 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 238000001514 detection method Methods 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 4
- 238000011579 SCID mouse model Methods 0.000 description 4
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000013394 immunophenotyping Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000006902 nitrogenation reaction Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Environmental Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides a kind of people's Pancytopenia glucocorticoid drug-resistant cell strain CEM C7/HDR and its construction method and application, and deposit number is CCTCC NO：C2017233, the cell line is induction object with Pancytopenia glucocorticoid sensitive cells strain CEM C7 14, simulate Pancytopenia cell living environment in marrow, it obtains stablizing glucocorticoid drug resistant cell line CEM C7/HDR using 0.25 μM of dexamethasone, 1 Fiber differentiation, the half-inhibition concentration to dexamethasone is 1500 times of parental cell or more.The present invention provides new cell model to recur the research of refractory people's acute lymphoblastic leukemia and biological medicine research and development, has larger practical value in the application for exploring the drug resistant pathogenesis of people's Pancytopenia glucocorticoid, the refractory mechanism of recurrence and reversing drug resistance medicament research and development.
Description
Technical field
The invention belongs to field of biomedicine technology, more particularly to a kind of people's Pancytopenia sugar cortical hormone
Plain drug-resistant cell strain and its construction method and application.
Background technology
Acute lymphoblastic leukemia（acute lymphoblastic leukemia, ALL）The childhood of being, is most common
Malignant tumour, although nearly 50 years, the prognosis of children ALL achieved rapid progress, and 5 years survival rates are carried from the 10% of 1960s
Height to 90%, but still have 10~20% patient it is refractory, recurrence, poor prognosis.Due to the high incidence of ALL children below 15 years old,
It is still the major reason for causing pediatric tumor death.Pancytopenia（T-ALL）It is one group and comes from T systems
The malignant clone disease of lymphoid precursor cell or lymphoblast accounts for the 10~15% of children ALL, and adult T-ALL ratios are high
In children, generally 20~25%, prognosis is significantly worse than B-ALL.T-ALL patient more than 70% belongs to high-risk ALL, is easy to early stage
Recurrence, 5 years survival rates are 40~70%.
Glucocorticoid（Glucocorticoid, GC）Drug resistance is ALL recurrences, refractory one of the major reasons.GC can be special
Different in nature inducing malignant lymphopoiesis is stagnated and inspires apoptosis, is always treatment ALL and other lymph source property malignant tumours
One of choice drug, nearly all ALL Combination chemotherapies include GC.At present in chemotherapy regimen common GC be prednisone and
Dexamethasone.GC sensibility is that children's ALL clinical risks degree is grouped, one of important indicator of guiding treatment and judging prognosis, GC
Drug resistance is clinical treatment problem urgently to be resolved hurrily.Therefore, T-ALL GC mdr cell models are established, it will help illustrate GC drug resistances
Molecule mechanism, find early stage accurate early warning GC resistant organism markers, improve leukemia risk degree parting, specify reversing drug resistance
Therapy target, establish the chemotherapy regimen of personalized high-efficiency low-toxicity；The difficult point of recurrence ALL treatments refractory at present is advantageously accounted for,
Children and adults ALL or even other lymph source property tumor cure rates are further improved, improve patient's long term survival quality, it is great
Clinical value.
Drug screening method is the common method for establishing tumor drug resistance cell line, and particular technique is divided into two kinds, first, progressively increasing
Add drug concentration, successive induction method, second is that heavy dose of impact intermittent administration method or two methods combine practicality.By above-mentioned
Method has been set up the drug-resistant cell strain of kinds of tumors both at home and abroad at present, but longer the time required to obtaining drug-resistant cell strain,
It needs to carry out screening pressurization to cell with drug more than June, and in experimentation, to maintain resistant characterization.CEM-C7-14 is T-
ALL cell lines come from 1964 from 3 years old CCRF-CEM cell line that foundation is separated in girl's white man peripheral blood, 1977
Professor Thompson therefrom selects monoclonal, obtains the CEM-C7-14 cells to GC sensitivities, CEM-C7-14 cells are to GC height
Sensitivity, 48 it is small when to the half-inhibition concentration of dexamethasone at 0.037 ± 0.003 μM, conventional medicament screening method be difficult
GC drug-resistant cell strains are successfully built on the basis of CEM-C7-14 cell lines.
The content of the invention
The present invention provides a kind of people's Pancytopenia glucocorticoid drug-resistant cell strain, Cell Names
It is people Pancytopenia cell line CEM-C7/HDR, deposit number is：CCTCC NO：C2017233, preservation day
Phase：On October 25th, 2017, depositary institution：China typical culture collection center.
The present invention also provides people's Pancytopenia glucocorticoid drug-resistant cell strain CEM-C7/HDR
Construction method：Its process is, first by people's Pancytopenia cell line CEM-C7-14 of exponential phase by 1~
3×104A/ml inoculations, it is 1~3 × 10 to be placed in culture to cell density under low-oxygen environment5A/ml（About 4 days time）Afterwards once
Property 0.25 μM of dexamethasone of addition, then proceed to culture to cell density be 2~10 × 105A/ml（About 4 weeks time）, so
It is placed under normoxic condition and expands culture, so as to obtain people's Pancytopenia glucocorticoid drug-resistant cell strain
CEM-C7/HDR。
In the above method, the hypoxia condition is that simulation Pancytopenia cell is survived micro-loop in marrow
Border, the normoxic condition can simulate the growing environment that Pancytopenia cell is released into peripheral blood from marrow.
Specific step is as follows：
（1）By people's Pancytopenia cell line CEM-C7-14 cellar cultures in the RPMI containing 10% hyclone
In 1640 complete mediums, 37 DEG C, 5%CO are placed in2, saturated humidity, 21%O2Normal oxygen incubator culture；
（2）Take step（1）It is middle to cultivate to the CEM-C7-14 cells of exponential phase, by 1~3 × 104A/ml is inoculated with into 6 holes
Plate is placed in simulation Pancytopenia cell and survives in marrow microenvironment（37℃、5%CO2, saturated humidity, 1%O2）
Hypoxemia incubator culture 4 days after, add in 0.25 μM of dexamethasone, continue culture 4 weeks, it is spare；
（3）By step（2）The cell that culture obtains is placed in simulation Pancytopenia cell and is released into periphery from marrow
The growing environment of blood（37℃、5% CO2, saturated humidity, 21%O2）Lower culture, when cell Proliferation to 1 × 106A/ml, it is conventional to pass
In generation, changes liquid, obtains people's Pancytopenia glucocorticoid drug-resistant cell strain CEM-C7/HDR.
People's Pancytopenia glucocorticoid drug-resistant cell strain CEM-C7/HDR that the present invention is obtained has
Following biological characteristics：
CEM-C7/HDR cells are as parental cell, the suspension growth in 1640 complete mediums of RPMI, based on circle,
With pleomorphism, in vitro culture well-grown, by 2 × 105A/ml density inoculation, passage in 2~3 days are once, continuous in vitro
Culture was more than 8 months, and more than 90 generations, population doublings were more than 280 generations, stablized multiplication, in good condition, Resistance index is more than for passage
1500.Character is constant after liquid nitrogen or Cryopreservation, recovery, keeps good resistant characterization.
The totally 5 weeks time of cell drug-resistant cell strain from handling to obtaining, cell height drug resistance, drug sensitivity test confirm
CEM-C7/HDR cells are more than 1500 to the Resistance index of dexamethasone.For population doublings at 10 generation, cell fills in rice over the ground
The Resistance index of pine reaches more than 3000, slightly falls after rise afterwards, and to after 100 generations, Resistance index stabilization is 1500 ~ 2500, no
Drug screening need to be used again, and resistant characterization is stablized.
The growth curve of CEM-C7/HDR cells is drawn using MTT and Trypan Blue cell counting, calculates cell times
When the increasing time is 18~20 small, multiplication rate is stablized, it is seen that split coil method.
The CEM-C7/HDR cell cycles are detected using PI decoration methods, it is seen that CEM-C7/HDR cells and its parental cell CEM-
Each phase distribution of C7-14 cells is basically identical.
Being tested using methylcellulose Semi-solid cell culture confirms that CEM-C7/HDR cell lines have high semisolid Clone formation
Ability.
Transcript profile sequencing finds that CEM-C7/HDR cells have 388 gene expression up-regulations, 269 bases compared to parental cell
Because expression is lowered.
CEM-C7/HDR cell inoculation NOD/SCID mouse have high oncogenicity, and tumor cells and the CEM- of in vitro culture
C7/HDR cell deriveds are consistent..
It is same that STR detections and Immunophenotyping, which analyze confirmation CEM-C7/HDR cells with parental cell CEM-C7-14,
Source.CEM-C7/HDR cells and CEM-C7-14 cell STR testing results are as shown in table 1 below, as seen from the results in Table 1, CEM-
C7/HDR is consistent with CEM-C7-14 cell deriveds.
Table 1：CEM-C7/HDR cells and CEM-C7-14 cell STR testing results
People's Pancytopenia cell line CEM-C7/HDR that the present invention is built has to be applied below：
（1）People Pancytopenia cell line CEM-C7/HDR is establishing the acute T Lymphocyte Glycogen Determinations cortical hormone of humanization
Application in plain leukaemia animal model, cell line CEM-C7/HDR has high oncogenicity, by CEM-C7/HDR cell inoculations
NOD/SCID mouse subcutaneously can touch lump in 10 days, and lump mushrooms out after 15 days, tumorigenesis rate 100%, and tumor cells
It is consistent with the CEM-C7/HDR cell deriveds of in vitro culture.
（2）People Pancytopenia cell line CEM-C7/HDR is resistance in screening or assessment treatment glucocorticoid
Medicine Pancytopenia drug and application in glucocorticoid medicine is reversed, by CEM-C7/HDR cells
Different chemotherapeutics, the changes such as observation growth and proliferation of cell, death, cycle are added in culture medium, and can clear and definite drug reverse
GC drug resistances obtain preliminary effective drug candidate, then drug candidate are used for above-mentioned Pancytopenia animal mould
Type detects the internal effect of drug, after ordinary circumstance, time-to-live, tumor size change and the drug effect of observing animal
In body situations such as apoptosis, necrosis and the change of other associated signal paths, so as to carry out curative effect evaluation and machine to drug candidate
System analysis.
（3）People Pancytopenia cell line CEM-C7/HDR is in the research acute T lymphs of glucocorticoid drug resistance
Application in chronic myeloid leukemia mechanism, cytomorphology, Biological characteristics, using light microscopic, electron microscopic observation cellular morphology knot
Structure and ultra microstructure compare the difference of CEM-C7/HDR and its parental cell CEM-C7-14 forms and Biological characteristics, using egg
The method of Bai Zuxue, full-length genome and metabolism group analyze CEM-C7/HDR and CEM-C7-14 cells, it is intended to seek
The discrepant Disease-causing gene of tool, albumen or metabolite are looked for, so as to the drug resistant pathogenesis of further investigated glucocorticoid.
（4）People Pancytopenia cell line CEM-C7/HDR is immunized establishing acute lymphoblastic leukemia
Learn and hematopoieticmicroenviron-ment research platform in application, NK cells, CAR-T or other immune antiboidies, ligand etc. are applied to
It is thin to sugared cortex drug-resistant leukemia to inquire into immunization therapy for CEM-C7/HDR and CEM-C7-14 cells and its humanized animal's model
Intracellular growth, immunity of organism and leukaemia development and the influence lapsed to；The dimensional culture environment of simulation marrow hemopoiesis tabernacle is established, is compared
The influence that different pharmaceutical including immunotherapy is treated and lapsed to glucocorticoid drug resistance acute lymphoblastic leukemia.
The invention has the advantages that：
1st, people's Pancytopenia cell line CEM-C7/HDR of the invention is white to recur refractory people's acute lymphoblastic
The research of blood disease and biological medicine research and development provide new cell model, are exploring people's Pancytopenia sugar cortical hormone
To hold out broad prospects in the application of the drug resistant pathogenesis of element, the refractory mechanism of recurrence and reversing drug resistance medicament research and development with it is larger
Practical value.
2nd, existing drug screening method structure drug-resistant cell strain is, it is necessary to be stepped up drug concentration, carry out successive induction or
Heavy dose impact intermittent administration or two methods combine, the above method is more difficult to the extremely sensitive cell of drug filter out it is resistance to
Medicine strain, and the more time is needed to carry out drug domestication to cell.People's Pancytopenia cell line CEM- of the present invention
The construction method of C7/HDR is impacted after using hypoxia condition culture with dexamethasone is heavy dose of, simulates clinical leukemia cell drug-resistance
Forming process, experimentation is simple, and modeling conditional stability can obtain drug-resistant cell strain, without using drug again in a short time
Screening pressurization is carried out to cell, modeling cost can be significantly reduced；Meanwhile this method can to the extremely sensitive cell modeling of drug,
Because under hypoxia condition, malignant cell to Treated with Chemotherapeutic Drugs object compared with normoxic condition when be more resistant to, the method can be used extensively
In various malignant cells, obtain to the drug resistance of different pharmaceutical or multi-medicament is screened simultaneously, obtain multidrug resistance
Cell line.
3rd, Resistance index is commonly used in the judgement of drug resistance of tumor cell degree（resistant index, RI）It represents, RI is
Mdr cell half-inhibition concentration（50% inhibitory concentration, IC50) with the ratio of parental cell IC50.
Drug resistance is divided into minuent by Snow etc. by the height of Resistance index（<5), moderate（5-15), height（> 15).The present invention is established
Drug-resistant cell strain CEM-C7/HDR its RI be 1500~2500, i.e., be to the IC50 of dexamethasone parental cell 1500~
2500 times.
Description of the drawings
Fig. 1 is CEM-C7/HDR and CEM-C7-14 cell observation figures under inverted phase contrast microscope（×400）；
Fig. 2 is the wooden Sa colored graph of CEM-C7/HDR and CEM-C7-14 cells Switzerland-Ji under ordinary optical microscope（×1000）；
Fig. 3 is half-inhibition concentration when dexamethasone is small to CEM-C7/HDR cytosiies 48（IC50）And its Resistance index
（RI）, wherein, A：Half-inhibition concentration when dexamethasone is small to CEM-C7/HDR cytosiies 48（IC50）；B：CEM-C7/
HDR is to the Resistance index of dexamethasone；PDL：Cell population doublings number（population doubling level）；
Fig. 4 is CEM-C7/HDR and CEM-C7-14 cell growth curves；
Fig. 5 schemes for flow cytometer detection CEM-C7/HDR and the CEM-C7-14 cell cycle, wherein, A：CEM-C7-14；B：CEM-C7/
HDR；
Fig. 6 is transcription group sequencing detection CEM-C7/HDR and CEM-C7-14 cellular gene expression differences, and wherein X-axis represents A
It is worth (the transformed Average expression levels of log2), Y-axis represents M values (the transformed fold differences of log2)；
Fig. 7 CEM-C7/HDR cell NOD/SCID mouse subcutaneous tumor forms lab diagram.
People Pancytopenia cell line CEM-C7/HDR, deposit number are：CCTCC NO：C2017233 is protected
Hide the date：On October 25th, 2017, depositary institution：China typical culture collection center preserves unit address：Hubei Province is military
No. 299 Wuhan Universitys of Han Shi Wuchang Districts Bayi Road are in the school（The first attached primary school of Wuhan University opposite）, Wuhan University's collection.
Specific embodiment
The present invention is in conjunction with specific embodiments described further invention, but the implementation of the present invention is not limited to that.
Method therefor is conventional method to following embodiments unless otherwise specified
Embodiment 1
The structure of people's Pancytopenia glucocorticoid drug-resistant cell strain CEM-C7/HDR of dexamethasone rapid induction
Construction method：
1. cell culture：Recovery people's Pancytopenia cell line CEM-C7-14 cells, are suspended in containing 10% tire ox
Serum（Thermo companies）1640 cell culture mediums of RPMI（Gibco companies）In, 37 DEG C, 5%CO2, saturated humidity, 21%O2
Normal oxygen incubator culture.
2. screening and culturing condition：The CEM-C7-14 cells of exponential phase in step 1 are taken, by 2 × 104A/ml inoculations
Enter 6 orifice plates, 2ml/ holes are respectively placed in 37 DEG C, 5%CO2, saturated humidity, 21%O2Normal oxygen incubator（Normal oxygen group）And 37 DEG C, 5%
CO2, saturated humidity, 1%O2Hypoxemia oxygen incubator（Hypoxia group）Culture, after 4 days, 0.25 μM of ground is added in normal oxygen and hypoxia group
Grouping culture using 3 holes of not dosing as control, is continued in Sai meter Song, each 3 hole.
On the addition of dexamethasone, the present embodiment be separately added into preliminary experiment 0.01 μM, 0.05 μM, 0.1 μM,
0.25 μM, 0.5 μM and 1 μM dexamethasone, it turns out that when less than 0.25 μM of concentration, cell can be effective in low-oxygen environment
Dexamethasone is resistant to, cell more difficult recovery multiplication capacity after heavy dose is impacted during more than 0.25 μM, therefore, the present invention uses
The dexamethasone of 0.25 μM of dosage.
3. build resistant models：After dosing 4 days, normal oxygen group complete cell death, hypoxia group after dexamethasone processing exist
Still there is survivaling cell after dexamethasone processing, continue hypoxemia culture, the normal oxygen culture of 4 weeks postpositions, when cell Proliferation to 1 × 106A/
Ml, routine passage change liquid, and half-inhibition concentration of the cell to dexamethasone is detected after 1 week, and calculate its Resistance index as 3200
± 29, this cell is named as CEM-C7/HDR.Monoclonal is chosen in methylcellulose culture, calculates cell doubling time, and detects
Cell cycle.
4. drug resistance tracks：By CEM-C7/HDR and its monoclonal cell, cellar culture, passage monthly weigh in normal oxygen
Half-inhibition concentration when reinspection survey cell is small to effects of dexamethasone 48, and Resistance index is calculated, the results show that in group times
After increasing 100 generation of number, CEM-C7/HDR and its monoclonal cell are to 60~70 μM of the half-inhibition concentration of dexamethasone, drug resistance
Exponential Stability is 1500~2500.
5. cell stablizes growth, does not influence its resistant characterization and biological characteristics through cryopreservation resuscitation repeatedly.
Embodiment 2
The growth of people's Pancytopenia glucocorticoid drug-resistant cell strain CEM-C7/HDR, biological characteristics and resistance to
Medicine CHARACTERISTICS IDENTIFICATION
（1）Morphological observation：Take the logarithm growth period CEM-C7/HDR cells and its parental cell CEM-C7-14 in fall
Micro- Microscopic observation living cells form is put, the results are shown in Figure 1, sees CEM-C7/HDR cells and its parental cell CEM-C7-14
Form is similar, equal suspension growth, based on circle, it is seen that pleomorphism cell, size are uneven.
Take the logarithm the CEM-C7/HDR cells in growth period and its parental cell CEM-C7-14, and routine smear is fixed, and Rui Shi-
Giemsa staining, in just putting micro- Microscopic observation, the results are shown in Figure 2, and CEM-C7/HDR cells and its parent CEM-C7-14 are thin
Born of the same parents' size, morphosis are similar.
（2）Mtt assay detects drug resistance of the cell to glucocorticoid：Be collected by centrifugation exponential phase CEM-C7/HDR and
CEM-C7-14 cells, it is 2 × 10 to adjust cell concentration respectively5A cell/ml, is inoculated in 96 orifice plates, per 100 μ l of hole, every group
3 multiple holes；The dexamethasone of increasing concen-trations is separately added into CEM-C7/HDR and CEM-C7-14 cells, wherein CEM-C7-14 is thin
Born of the same parents add in 0.0001~1 μM of dexamethasone, are incremented by by 10 times, and CEM-C7/HDR cells add in 0.1~1000 μM of dexamethasone,
It is incremented by by 10 times.Blank control and not dosing control group are set, when processing 48 is small, add in 10 μ l/ holes of 5mg/ml MTT, fully
Mixing, 37 DEG C be incubated 4 it is small when after add in the SDS of acidifying（10%SDS HCl containing 0.01M）, 100 μ l/hole, mixing.37 DEG C incubate
It educates overnight, the absorbance of secondary daily multi-function microplate reader detection 570nm wavelength（OD）.According to blank group, control group, fill in rice
The OD averages of pine group calculate the survival rate of cell.Cell survival rate=（OD dexamethasone average-OD blank averages）/（OD is compareed
Average-OD blank averages）×100%.Curve is drawn according to time, drug concentration, cell survival rate and calculates the suppression of dexamethasone half
Concentration processed.CEM-C7/HDR cells are CEM-C7/HDR cells half-inhibition concentration and parent to the Resistance index of glucocorticoid
The ratio of cell CEM-C7-14 half-inhibition concentrations.The results are shown in Figure 3, and CEM-C7/HDR cells are in population doublings 10
Dai Shi, cell are up to 128 μM to the half-inhibition concentration of dexamethasone, and Resistance index is up to 3200, to after 100 generations, cell
To the half-inhibition concentration stabilization of dexamethasone at 60~70 μM, Resistance index stabilization is 1500~2500.
（3）Growth curve and doubling time measure：The CEM-C7/HDR and CEM-C7-14 that exponential phase is collected by centrifugation are thin
Born of the same parents, adjustment cell concentration are 1 × 105A cell/ml, is inoculated in 6 orifice plates, puts 37 DEG C, 5%CO2、21%O27 are cultivated in incubator
My god, Trypan Blue living cell counting is used daily, and cell proliferative conditions are detected with mtt assay, with the accurate of clear and definite cell count
Property, cell suspension is added in 96 orifice plates, and per 100 μ l of hole, every group of 3 multiple holes set blank control, add in 5mg/ml MTT（Sigma
Company）10 μ l/ holes, abundant mixing, 37 DEG C be incubated 4 it is small when after add in the SDS of acidifying（10%SDS HCl containing 0.01M）, 100 μ l
/ hole, mixing.37 DEG C of overnight incubations, secondary daily multi-function microplate reader survey the absorbance of 570nm wavelength（OD）.Using the time as horizontal stroke
Coordinate, cell number are ordinate, draw cell growth curve, as shown in figure 4, CEM-C7/HDR cells and its parental cell CEM-
The growth of C7-14 cells is basically identical, when the doubling time is 18~20 small.
（4）PI decoration methods compare the cell cycle status of CEM-C7/HDR cells and its parental cell CEM-C7-14, as a result
As shown in figure 5, CEM-C7/HDR cells and each phase distribution of its parental cell CEM-C7-14 cells are basically identical.
（6）STR detections confirm CEM-C7/HDR cells and its parental cell CEM-C7-14 is same source.
（7）Flow cytometer detection cellular immunity parting confirms that CEM-C7/HDR cells and its parental cell CEM-C7-14 are same
Source expresses CD3, CD4, CD5 and CD7, does not express CD8, CD34 and HLA-DR.
（8）Transcript profile is sequenced, and the results are shown in Figure 6, finds CEM-C7/HDR cells compared to parental cell CEM-C7-14
There are 388 gene expression up-regulations, 269 down regulation of gene expression.
Embodiment 3
Establish the acute T lymphocytes glucocorticoid leukaemia animal model of humanization
NOD/SCID mouse are tested into knurl：CEM-C7/HDR cells in exponential phase are pressed 5 × 106/ 100 μ l/ only, connect
Kind is in female Balb/c (nu/nu) mouse（6 week old, 19~21g of weight）Apterium is subcutaneous；The next day observe inoculation position tumour
Generation situation.The results are shown in Figure 7, and inoculation can touch grain of rice size lump after 10 days in nude mice by subcutaneous, tumour after being inoculated with 15 days
It mushrooms out, every 3 days measurement Tumor sizes, it is seen that lump volume was from 762 mm of the 15th day3Grow into the 3527 of the 21st day
mm3.Take tumor mass that cell suspension is made after 15 days, immunophenotyping and STR detections confirm that tumor mass separation cell and CEM-C7/HDR are thin
Born of the same parents are same source.
Claims (10)
1. a kind of people's Pancytopenia glucocorticoid drug-resistant cell strain, Cell Name is that the acute T lymphs of people are thin
Born of the same parents leukemia cell line CEM-C7/HDR, deposit number CCTCCNO：C2017233.
2. the construction method of people's Pancytopenia cell line CEM-C7/HDR, feature described in a kind of claim 1
It is：It is 1 that people's Pancytopenia cell line CEM-C7-14 first is placed in culture to cell density under hypoxia condition
~3 × 105After a/ml, disposably add in 0.25 μM of dexamethasone, then proceed to hypoxemia culture to cell density for 2~10 ×
105A/ml is finally placed under normoxic condition and expands culture, resistance to so as to obtain people's Pancytopenia glucocorticoid
Medicine cell line CEM-C7/HDR.
3. the construction method of people's Pancytopenia cell line CEM-C7/HDR according to claim 2, special
Sign is：The hypoxia condition refers to that simulate Pancytopenia cell survives microenvironment in marrow, the normal oxygen
Condition refers to simulate the growing environment that Pancytopenia cell is released into peripheral blood from marrow.
4. the construction method of people's Pancytopenia cell line CEM-C7/HDR according to claim 2, special
Sign is：People's Pancytopenia cell line CEM-C7-14 is the CEM-C7-14 cells of exponential phase, is pressed
1~3 × 104A/ml inoculations are placed in hypoxia condition culture.
5. the construction method of people's Pancytopenia cell line CEM-C7/HDR according to claim 3, special
Sign is：Existence microenvironment of the simulation Pancytopenia cell in marrow refers to 37 DEG C, 5%CO2, saturation
Humidity, 1%O2Environment.
6. the construction method of people's Pancytopenia cell line CEM-C7/HDR according to claim 3, special
Sign is：It is described simulation Pancytopenia cell from marrow be released into peripheral blood growing environment refer to 37 DEG C, 5%
CO2, saturated humidity, 21%O2Environment.
7. people Pancytopenia cell line CEM-C7/HDR is establishing the acute T leaching of humanization glucocorticoid drug resistance
Application in bar chronic myeloid leukemia animal model.
8. people Pancytopenia cell line CEM-C7/HDR is acute in screening or assessment treatment glucocorticoid drug resistance
Application in T lymphocytic leukemia drugs.
9. people Pancytopenia cell line CEM-C7/HDR is in the research acute T lymphocytes of glucocorticoid drug resistance
Application in leukaemia mechanism, cytomorphology, Biological characteristics.
10. people Pancytopenia cell line CEM-C7/HDR establish acute lymphoblastic leukemia immunology and
Application in hematopoieticmicroenviron-ment research platform.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810072930.6A CN108048402B (en) | 2018-01-25 | 2018-01-25 | A kind of people's Pancytopenia glucocorticoid drug-resistant cell strain and its construction method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810072930.6A CN108048402B (en) | 2018-01-25 | 2018-01-25 | A kind of people's Pancytopenia glucocorticoid drug-resistant cell strain and its construction method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108048402A true CN108048402A (en) | 2018-05-18 |
| CN108048402B CN108048402B (en) | 2019-01-29 |
Family
ID=62124803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810072930.6A Active CN108048402B (en) | 2018-01-25 | 2018-01-25 | A kind of people's Pancytopenia glucocorticoid drug-resistant cell strain and its construction method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108048402B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112877290A (en) * | 2021-03-04 | 2021-06-01 | 浙江大学 | Human T lymphoblastic leukemia/lymphoma cell strain and application thereof |
| CN113046319A (en) * | 2021-03-18 | 2021-06-29 | 浙江大学 | Human acute myeloid leukemia cell strain and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104004715A (en) * | 2014-05-21 | 2014-08-27 | 兰州大学 | Human leukemia HL-60 cell drug-resistance cell line HL-60/RS cell and preparation method thereof |
| CN107233571A (en) * | 2017-06-21 | 2017-10-10 | 中国人民解放军第三军医大学第附属医院 | The application of ICBP90 antibody and its expression inhibiting agent in the medicine for promoting glucocorticoid treatment effect is prepared |
-
2018
- 2018-01-25 CN CN201810072930.6A patent/CN108048402B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104004715A (en) * | 2014-05-21 | 2014-08-27 | 兰州大学 | Human leukemia HL-60 cell drug-resistance cell line HL-60/RS cell and preparation method thereof |
| CN107233571A (en) * | 2017-06-21 | 2017-10-10 | 中国人民解放军第三军医大学第附属医院 | The application of ICBP90 antibody and its expression inhibiting agent in the medicine for promoting glucocorticoid treatment effect is prepared |
Non-Patent Citations (2)
| Title |
|---|
| AH BEESLEY,ET AL.: "Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism", 《MOLECULAR DIAGNOSTICS》 * |
| JOHN A. MARWICK,ET AL.: "Oxygen levels determine the ability of glucocorticoids to influence neutrophil survival in inflammatory environments", 《JOURNAL OF LEUKOCYTE BIOLOGY》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112877290A (en) * | 2021-03-04 | 2021-06-01 | 浙江大学 | Human T lymphoblastic leukemia/lymphoma cell strain and application thereof |
| CN112877290B (en) * | 2021-03-04 | 2021-11-30 | 浙江大学 | Human T lymphoblastic leukemia/lymphoma cell strain and application thereof |
| CN113046319A (en) * | 2021-03-18 | 2021-06-29 | 浙江大学 | Human acute myeloid leukemia cell strain and application thereof |
| CN113046319B (en) * | 2021-03-18 | 2022-11-08 | 浙江大学 | Human acute myeloid leukemia cell strain and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108048402B (en) | 2019-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108315302B (en) | A kind of people's B-lineage Acute Lymphocyte Leukemia glucocorticoid drug-resistant cell strain and its construction method and application | |
| CN105848793B (en) | Material selectivity is delivered to cell | |
| CN103756967B (en) | Application of the monoclonal antibody coupling immunomagnetic beads of anti-HLA-G in tumour cell sorting | |
| CN104894065B (en) | A kind of cultural method of NK cell culture mediums and NK cells | |
| CN108048402B (en) | A kind of people's Pancytopenia glucocorticoid drug-resistant cell strain and its construction method and application | |
| CN105924533A (en) | ROR1 specific chimeric antigen receptor and application thereof | |
| CN105085677B (en) | Anti-vegf R2 source of people nano antibody NTV1 and its preparation method and application | |
| Chen et al. | Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model | |
| CN106086078B (en) | A kind of CAR T cell toxicities indicate carrier | |
| Puntigam et al. | Immune checkpoint expression on immune cells of HNSCC patients and modulation by chemo-and immunotherapy | |
| Ao et al. | Evaluation of cancer immunotherapy using mini-tumor chips | |
| CN107064085A (en) | Test Procedur of Splenic Natural Killer Cell Activity | |
| CN106222141A (en) | NK cell culture fluid and cell culture processes | |
| Gallo et al. | A new bioassay platform design for the discovery of small molecules with anticancer immunotherapeutic activity | |
| CN108997478A (en) | A kind of polypeptide and its application with immunologic test point antagonistic activity | |
| WO2024001509A1 (en) | Niraparib-resistant human ovarian cancer cell line and use thereof | |
| CN109097334A (en) | Ph+ B-lineage Acute Lymphocyte Leukemia KQBL-84 cell strain and its construction method and application | |
| CN104774756A (en) | Chip and method for microfluidic drug screening on basis of SERS (surface-enhanced Raman scattering) detection technology | |
| CN104181290B (en) | A kind of analysis method for evaluating thrombopoietin receptor stimulating agent external activity | |
| Wu et al. | Cordycepin inhibits growth and metastasis formation of MDA-MB-231 xenografts in nude mice by modulating the hedgehog pathway | |
| CN108588019B (en) | A kind of external evoked naive B cell is divided into the method and its condition of culture of modulability B cell | |
| CN108795868A (en) | A kind of Human colorectal carcinoma Cetuximab drug-resistant cell strain and its application | |
| Gruijs et al. | NK cell-dependent antibody-mediated immunotherapy is improved in vitro and in vivo when combined with agonists for Toll-like receptor 2 in head and neck cancer models | |
| Wang et al. | Chemokine receptors CCR6 and PD1 blocking scFv E27 enhances anti-EGFR CAR-T therapeutic efficacy in a preclinical model of human non-small cell lung carcinoma | |
| WO2022183749A1 (en) | Human t-lymphoblastic leukaemia/lymphoma cell strain and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Gu Ling Inventor after: Gao Ju Inventor after: Wang Yufang Inventor after: Zhang Yanle Inventor after: Yuan Lixing Inventor before: Gu Ling Inventor before: Gao Ju Inventor before: Wang Yufang Inventor before: Zhang Yanle Inventor before: Yuan Lixing |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |